Esketamine ( DrugBank: Esketamine )

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
4	Primary lateral sclerosis	1
70	Spinal stenosis	1

2. Amyotrophic lateral sclerosis

Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-000142-18-FI (EUCTR)	09/05/2018	08/05/2018	Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative care	Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care	Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE Trade Name: Ketanest-S INN or Proposed INN: ESKETAMINE	Turku University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Finland

Clinical trials : 7 / Drugs : 17 - (DrugBank : 9) / Drug target genes : 19 - Drug target pathways : 32

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-000142-18-FI (EUCTR)	09/05/2018	08/05/2018	Feasibility and effects of subcutaneously given combination of dexmedetomidine and ketamine in ALS patients receiving palliative care	Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care	Amyotrophic lateral sclerosis (ALS) MedDRA version: 20.1;Level: LLT;Classification code 10036704;Term: Primary lateral sclerosis;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Dexdor INN or Proposed INN: DEXMEDETOMIDINE Trade Name: Ketanest-S INN or Proposed INN: ESKETAMINE	Turku University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 4	Finland

Clinical trials : 96 / Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-000747-26-FI (EUCTR)	27/04/2012	02/04/2012	Ketamine to reduce postoperative pain in back surgery	Administration of S-Ketamine during spinal surgery to reduce postoperative pain	adult patients undergoing spinal surgery MedDRA version: 14.1;Level: LLT;Classification code 10041595;Term: Spinal stenosis lumbar;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]	Trade Name: Ketanest-S Product Name: Ketanest-S Other descriptive name: ESKETAMINE HYDROCHLORIDE	Helsinki Universiy Central Hospital	NULL	Not Recruiting			Female: yes Male: yes	192	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Finland